Avalo Therapeutics Says On Aug 14, Got Notice From Apollo AP43 Alleging That Co Is In Breach Of License Agreement Between Them Dated July 29, 2022
Portfolio Pulse from Benzinga Newsdesk
Avalo Therapeutics has received a notice from Apollo AP43 alleging that the company is in breach of a license agreement between them dated July 29, 2022.
August 14, 2023 | 9:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Avalo Therapeutics is alleged to have breached a license agreement with Apollo AP43, which could potentially lead to legal complications.
The allegation of a breach of a license agreement could lead to legal complications for Avalo Therapeutics. This could potentially impact the company's operations and financials, which could negatively affect the stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100